Partnership expands oncology diagnostics across Europe

A fresh agreement between Bio-Rad Laboratories and Korean oncology specialist Gencurix will bring a new wave of molecular diagnostics to clinical labs across Europe. The deal makes Bio-Rad the exclusive distributor of Gencurix’s CE-IVD Droplex™ digital PCR testing kits, which are powered by Bio-Rad’s Droplet Digital™ PCR (ddPCR™) platform.

The Droplex assays are designed for highly sensitive detection of mutations from liquid biopsy and FFPE samples, with applications across major cancers such as melanoma, colorectal cancer, and non-small cell lung cancer. Used alongside Bio-Rad’s QXDx™ ddPCR systems, the kits aim to give clinicians sharper tools for guiding treatment decisions.

The extended partnership builds on an already established relationship between the two companies but takes it further with joint marketing and collaborative development initiatives. For Gencurix, the agreement validates the clinical potential of its technology, while Bio-Rad strengthens its oncology diagnostics portfolio in one of the world’s most important markets.

“This partnership gives European labs access to highly sensitive diagnostic tools and will help physicians make more informed treatment decisions,” said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories.

“Expanding with Bio-Rad marks a milestone for Gencurix and accelerates access to our oncology diagnostics across Europe,” added Sang Rae Cho, CEO of Gencurix. 

More information online